Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Lexaria Bioscience (LEXX) over the last 15 years, with Q4 2025 value amounting to -$984098.0.

  • Lexaria Bioscience's Cash from Operations rose 6390.02% to -$984098.0 in Q4 2025 from the same period last year, while for Nov 2025 it was -$8.7 million, marking a year-over-year decrease of 3390.61%. This contributed to the annual value of -$10.5 million for FY2025, which is 11073.56% down from last year.
  • Per Lexaria Bioscience's latest filing, its Cash from Operations stood at -$984098.0 for Q4 2025, which was up 6390.02% from -$2.6 million recorded in Q3 2025.
  • Over the past 5 years, Lexaria Bioscience's Cash from Operations peaked at -$619614.0 during Q1 2024, and registered a low of -$3.6 million during Q2 2025.
  • Its 5-year average for Cash from Operations is -$1.5 million, with a median of -$1.3 million in 2022.
  • Within the past 5 years, the most significant YoY rise in Lexaria Bioscience's Cash from Operations was 6390.02% (2025), while the steepest drop was 18307.54% (2025).
  • Quarter analysis of 5 years shows Lexaria Bioscience's Cash from Operations stood at -$1.2 million in 2021, then decreased by 6.77% to -$1.2 million in 2022, then rose by 5.11% to -$1.2 million in 2023, then plummeted by 130.7% to -$2.7 million in 2024, then soared by 63.9% to -$984098.0 in 2025.
  • Its Cash from Operations stands at -$984098.0 for Q4 2025, versus -$2.6 million for Q3 2025 and -$3.6 million for Q2 2025.